HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · Real-Time Price · USD
2.170
+0.130 (6.37%)
At close: Jan 24, 2025, 4:00 PM
2.180
+0.010 (0.46%)
After-hours: Jan 24, 2025, 4:15 PM EST
HOOKIPA Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for HOOKIPA Pharma stock have an average target of 10.67, with a low estimate of 2.00 and a high estimate of 23. The average target predicts an increase of 391.71% from the current stock price of 2.17.
Analyst Consensus: Buy
* Price targets were last updated on Dec 20, 2024.
Analyst Ratings
The average analyst rating for HOOKIPA Pharma stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 0 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 10, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $48 → $2 | Buy → Hold | Downgrades | $48 → $2 | -7.83% | Dec 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $24 → $7 | Buy | Maintains | $24 → $7 | +222.58% | Nov 21, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $50 → $48 | Buy | Maintains | $50 → $48 | +2,111.98% | Nov 15, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $23 → $24 | Buy | Maintains | $23 → $24 | +1,005.99% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
50.08M
from 20.13M
Increased by 148.80%
Revenue Next Year
19.64M
from 50.08M
Decreased by -60.79%
EPS This Year
-1.59
from -8.63
EPS Next Year
-4.00
from -1.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 55.7M | 26.3M | 1.1M | |||
| Avg | 50.1M | 19.6M | 1.0M | |||
| Low | 43.7M | 13.2M | 980,000 |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 176.9% | -47.6% | -94.7% | |||
| Avg | 148.8% | -60.8% | -94.8% | |||
| Low | 117.1% | -73.6% | -95.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.70 | -1.99 | -8.89 | |
| Avg | -1.59 | -4.00 | -8.64 | |
| Low | -2.39 | -5.82 | -8.30 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.